Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1800 (2.78%) ($5.1800 - $5.1800) on Thu. Mar. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.18% (three month average) | RSI | 63 | Latest Price | $5.1800(2.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 3.5% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) EMHY(23%) TBT(23%) BWX(21%) EWY(18%) EWI(17%) | Factors Impacting ADMS price | ADMS will decline at least -2.59% in a week (0% probabilities). BND(-43%) UUP(-33%) TLT(-26%) TAN(-16%) INDA(-15%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.59% (StdDev 5.18%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.32(-2.63%) | 10 Day Moving Average | $5.33(-2.81%) | 20 Day Moving Average | $5.14(0.78%) | To recent high | -22.2% | To recent low | 3.2% | Market Cap | $146m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |